×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
OVID – ovid therapeutics inc. (US:NASDAQ)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
OVID
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
4/15
08:41 am
ovid
Ovid Therapeutics (OVID) had its "outperform" rating reaffirmed by Wedbush. They now have a $7.00 price target on the stock.
Medium
Report
Ovid Therapeutics (OVID) had its "outperform" rating reaffirmed by Wedbush. They now have a $7.00 price target on the stock.
4/14
06:43 pm
ovid
Ovid Therapeutics Inc. (OVID) Discusses KCC2 Deep Dive and Pipeline Advances in CNS Disorders Transcript [Seeking Alpha]
Medium
Report
Ovid Therapeutics Inc. (OVID) Discusses KCC2 Deep Dive and Pipeline Advances in CNS Disorders Transcript [Seeking Alpha]
4/9
08:15 am
ovid
Ovid Therapeutics (OVID) had its price target raised by HC Wainwright from $2.00 to $4.00. They now have a "buy" rating on the stock.
High
Report
Ovid Therapeutics (OVID) had its price target raised by HC Wainwright from $2.00 to $4.00. They now have a "buy" rating on the stock.
4/8
08:00 am
ovid
Ovid Therapeutics to Host Potassium-Chloride Co-transporter 2 (KCC2) Deep Dive R&D Event on Tuesday, April 14
Low
Report
Ovid Therapeutics to Host Potassium-Chloride Co-transporter 2 (KCC2) Deep Dive R&D Event on Tuesday, April 14
3/27
08:02 am
ovid
Ovid Therapeutics (OVID) had its "buy" rating reaffirmed by BTIG Research. They now have a $4.00 price target on the stock.
Medium
Report
Ovid Therapeutics (OVID) had its "buy" rating reaffirmed by BTIG Research. They now have a $4.00 price target on the stock.
3/20
08:44 am
ovid
Ovid Therapeutics (OVID) had its price target raised by Wedbush from $5.00 to $7.00. They now have an "outperform" rating on the stock.
High
Report
Ovid Therapeutics (OVID) had its price target raised by Wedbush from $5.00 to $7.00. They now have an "outperform" rating on the stock.
3/20
07:46 am
ovid
Ovid Therapeutics: Seizing The Moment With Phase 2 Ready Assets And PIPE Funding [Seeking Alpha]
Low
Report
Ovid Therapeutics: Seizing The Moment With Phase 2 Ready Assets And PIPE Funding [Seeking Alpha]
3/18
05:03 pm
ovid
Ovid Therapeutics Inc. (OVID) Q4 2025 Earnings Call Transcript [Seeking Alpha]
Low
Report
Ovid Therapeutics Inc. (OVID) Q4 2025 Earnings Call Transcript [Seeking Alpha]
Date
Time
Symbol
Company Name
Action
%Chg
Date
Time
Action
From
To
Firm
Impact
%Chg
Date
Time
Symbol
Headline
Impact
4/9
05:15 pm
ovid
Form 4 Ovid Therapeutics Inc. For: Apr 07 Filed by: Fitzgerald Kevin Joseph
Low
Report
Form 4 Ovid Therapeutics Inc. For: Apr 07 Filed by: Fitzgerald Kevin Joseph
4/9
05:15 pm
ovid
Form 4 Ovid Therapeutics Inc. For: Apr 07 Filed by: PAPADOPOULOS STELIOS
Low
Report
Form 4 Ovid Therapeutics Inc. For: Apr 07 Filed by: PAPADOPOULOS STELIOS
4/9
05:15 pm
ovid
Form 4 Ovid Therapeutics Inc. For: Apr 07 Filed by: Friedman Bart
Low
Report
Form 4 Ovid Therapeutics Inc. For: Apr 07 Filed by: Friedman Bart
3/25
09:18 pm
ovid
Form 4 Ovid Therapeutics Inc. For: Mar 23 Filed by: LEVIN JEREMY M
Low
Report
Form 4 Ovid Therapeutics Inc. For: Mar 23 Filed by: LEVIN JEREMY M
3/18
04:49 pm
ovid
Form S-8 Ovid Therapeutics Inc.
Low
Report
Form S-8 Ovid Therapeutics Inc.
3/18
04:27 pm
ovid
Form 10-K Ovid Therapeutics Inc. For: Dec 31
Low
Report
Form 10-K Ovid Therapeutics Inc. For: Dec 31
3/18
07:39 am
ovid
Form 8-K Ovid Therapeutics Inc. For: Mar 17
Low
Report
Form 8-K Ovid Therapeutics Inc. For: Mar 17
3/2
04:31 pm
ovid
Form 4 Ovid Therapeutics Inc. For: Feb 23 Filed by: ALEXANDER MARGARET A.
Medium
Report
Form 4 Ovid Therapeutics Inc. For: Feb 23 Filed by: ALEXANDER MARGARET A.
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
9/24
Form 8-K Ovid Therapeutics Inc. For: Sep 23
25.5%
6/18 Form 8-K Ovid Therapeutics Inc. For: Jun 18 14.2%
11/29 RBC bullish on OVID's 2020 catalysts [Seeking Alpha] 10.4%
9/23 Form 8-K Ovid Therapeutics Inc. For: Sep 23 10.3%
8/17 Ovid Therapeutics Inc (NASDAQ: OVID) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $2.00 price target on the stock. 9.8%
7/1 Ovid Therapeutics Inc (NASDAQ: OVID) had its "buy" rating re-affirmed by analysts at Cowen Inc. 9.6%
7/18 Ovid Therapeutics Inc (NASDAQ: OVID) was downgraded by analysts at Zacks Investment Research from a "hold" rating to a "sell" rating. 9.4%
10/10 Form 4 Ovid Therapeutics Inc. For: Oct 08 Filed by: LEVIN JEREMY M 7.5%
11/15 Form 4 Ovid Therapeutics Inc. For: Nov 13 Filed by: Bernstein Karen 6.6%
12/20 Form 4 Ovid Therapeutics Inc. For: Dec 18 Filed by: Perone Thomas Michael 6.0%
6/18 Form 8-K Ovid Therapeutics Inc. For: Jun 18 14.2%
11/29 RBC bullish on OVID's 2020 catalysts [Seeking Alpha] 10.4%
9/23 Form 8-K Ovid Therapeutics Inc. For: Sep 23 10.3%
8/17 Ovid Therapeutics Inc (NASDAQ: OVID) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $2.00 price target on the stock. 9.8%
7/1 Ovid Therapeutics Inc (NASDAQ: OVID) had its "buy" rating re-affirmed by analysts at Cowen Inc. 9.6%
7/18 Ovid Therapeutics Inc (NASDAQ: OVID) was downgraded by analysts at Zacks Investment Research from a "hold" rating to a "sell" rating. 9.4%
10/10 Form 4 Ovid Therapeutics Inc. For: Oct 08 Filed by: LEVIN JEREMY M 7.5%
11/15 Form 4 Ovid Therapeutics Inc. For: Nov 13 Filed by: Bernstein Karen 6.6%
12/20 Form 4 Ovid Therapeutics Inc. For: Dec 18 Filed by: Perone Thomas Michael 6.0%
TOP News Decliners
3/12
Ovid Therapeutics Inc (NASDAQ: OVID) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating.
-28.1%
10/3 Ovid Therapeutics Announces Proposed Concurrent Public Offerings of Common Stock and Preferred Stock -26.8%
3/11 Ovid Therapeutics Reports Fourth Quarter and Full Year 2019 Financial Results, Provides Corporate Update for 2020 -18.8%
3/6 Ovid Therapeutics Inc (NASDAQ: OVID) had its "buy" rating re-affirmed by analysts at LADENBURG THALM/SH SH. They now have a $20.00 price target on the stock. -13.4%
5/7 Q1/2019 3/31/2019 EPS -0.460 ZacksConsensus N/A ActVsEst N/A - N/A -11.3%
6/27 Form 8-K Ovid Therapeutics Inc. For: Jun 27 -7.5%
9/26 Ovid Therapeutics Inc (NASDAQ: OVID) was given a new $14.00 price target on by analysts at Piper Jaffray Companies. They now have a "buy" rating on the stock. -6.9%
2/14 Form SC 13G/A Ovid Therapeutics Inc. Filed by: LEVIN JEREMY M -6.8%
11/4 Form 4 Ovid Therapeutics Inc. For: Nov 01 Filed by: Daly Timothy -5.9%
8/22 Ovid Therapeutics Inc (NASDAQ: OVID) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating. -5.6%
10/3 Ovid Therapeutics Announces Proposed Concurrent Public Offerings of Common Stock and Preferred Stock -26.8%
3/11 Ovid Therapeutics Reports Fourth Quarter and Full Year 2019 Financial Results, Provides Corporate Update for 2020 -18.8%
3/6 Ovid Therapeutics Inc (NASDAQ: OVID) had its "buy" rating re-affirmed by analysts at LADENBURG THALM/SH SH. They now have a $20.00 price target on the stock. -13.4%
5/7 Q1/2019 3/31/2019 EPS -0.460 ZacksConsensus N/A ActVsEst N/A - N/A -11.3%
6/27 Form 8-K Ovid Therapeutics Inc. For: Jun 27 -7.5%
9/26 Ovid Therapeutics Inc (NASDAQ: OVID) was given a new $14.00 price target on by analysts at Piper Jaffray Companies. They now have a "buy" rating on the stock. -6.9%
2/14 Form SC 13G/A Ovid Therapeutics Inc. Filed by: LEVIN JEREMY M -6.8%
11/4 Form 4 Ovid Therapeutics Inc. For: Nov 01 Filed by: Daly Timothy -5.9%
8/22 Ovid Therapeutics Inc (NASDAQ: OVID) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating. -5.6%
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: